Evidence map›Paper›PMID 35675510›Full record

ArticleBrain : a journal of neurology2022

Phenotypic and genetic spectrum of ATP6V1A encephalopathy: a disorder of lysosomal homeostasis.

Renzo Guerrini, Davide Mei, Katalin Kerti-Szigeti, Sara Pepe, Mary Kay Koenig, Gretchen Von Allmen, Megan T Cho, Kimberly McDonald, Janice Baker, Vikas Bhambhani and 43 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02450851 (Clinical and Genetic Evaluation of Patients With Undiagnosed Disorders Through the Undiagnosed Diseases Network), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02450851 recruitingnot on this map

Clinical and Genetic Evaluation of Patients With Undiagnosed Disorders Through the Undiagnosed Diseases Network

TypeobservationalSponsorNational Human Genome Research Institute (NHGRI)Ran2015 to 2028Enrolled20,000ConditionsGenetic Disease
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 10 countries.

Renzo GuerriniNeuroscience Department, Children's Hospital Meyer, University of Florence, Florence, Italy.ORCID 0000-0002-7272-7079
Davide MeiNeuroscience Department, Children's Hospital Meyer, University of Florence, Florence, Italy.
Katalin Kerti-SzigetiInstitute of Science and Technology Austria (ISTA), Klosterneuburg, Austria.
Sara PepeDepartment of Experimental Medicine, University of Genoa, Italy.
Mary Kay KoenigDepartment of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas McGovern Medical School, Houston, TX, USA.
Gretchen Von AllmenDepartment of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas McGovern Medical School, Houston, TX, USA.
Megan T ChoGeneDx, Gaithersburg, MD 20877, USA.
Kimberly McDonaldPediatric Neurology, University of Mississippi Medical Center, Jackson, MS, USA.
Janice BakerGenetics and Genomics, Children's Minnesota, Minneapolis, MN, USA.
Vikas BhambhaniGenetics and Genomics, Children's Minnesota, Minneapolis, MN, USA.
Zöe PowisAmbry Genetics, Aliso Viejo, CA, USA.
Lance RodanDivision of Genetics and Genomics and Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Rima NabboutReference Centre for Rare Epilepsies, Department of Genetics, Necker Enfants Malades Hospital, APHP, member of ERN EpiCARE, Université de Paris, Paris, France.
Giulia BarciaReference Centre for Rare Epilepsies, Department of Genetics, Necker Enfants Malades Hospital, APHP, member of ERN EpiCARE, Université de Paris, Paris, France.
Jill A RosenfeldDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-5664-7987
Carlos A BacinoDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Cyril MignotAPHP, Sorbonne Université, Départément de Génétique, Centre de Référence Déficiences Intellectuelles de Causes Rares, Paris, France.
Lillian H PowerPediatric Neurology, Stead Family Department of Pediatrics, University of Iowa Stead Family Children's Hospital, Iowa City, IA, USA.
Catharine J HarrisDepartment of Pediatric Genetics, University of Missouri Medical Center, Columbia, MO 65212, USA.
Dragan MarjanovicDanish Epilepsy Centre Filadelfia, Adult Neurology, Dianalund, Denmark.
Rikke S MøllerDepartment of Epilepsy Genetics and Personalized Treatment, Danish Epilepsy Center Filadelfia, Dianalund, Denmark.
Trine B HammerDepartment of Epilepsy Genetics and Personalized Treatment, Danish Epilepsy Center Filadelfia, Dianalund, Denmark.
DDD Study
Riikka Keski FilppulaDepartment of Clinical Genetics, Oulu University Hospital, Medical Research Center Oulu and PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Päivi VieiraClinic for Children and Adolescents, Oulu University Hospital, Medical Research Center Oulu and PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Clara HildebrandtDivision of Genetics and Genomics, Metabolism Program, Boston Children's Hospital, Boston, MA, USA.
Stephanie SacharowBoston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Undiagnosed Diseases Network
Luca MaraglianoCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genova, Italy.
Fabio BenfenatiCenter for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genova, Italy.ORCID 0000-0002-0653-8368
Katherine LachlanWessex Clinical Genetics Service, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Andreas BennecheDepartment of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
Florence PetitCHU Lille, Clinique de Génétique, F-59000 Lille, France.
Jean Madeleine de Sainte AgatheLaboratoire de Biologie Médicale Multi Sites SeqOIA, Laboratoire de Médecine Génomique, APHP. Sorbonne Université, Paris, France.
Barbara HallinanDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Yue SiGeneDx, Gaithersburg, MD 20877, USA.
Ingrid M WentzensenGeneDx, Gaithersburg, MD 20877, USA.
Fanggeng ZouGeneDx, Gaithersburg, MD 20877, USA.
Vinodh NarayananNeurogenomics Division, Center for Rare Childhood Disorders, Translational Genomics Research Institute (TGen), Phoenix, AZ 85012, USA.
Naomichi MatsumotoDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID 0000-0001-9846-6500
Alessandra BoncristianoNeuroscience Department, Children's Hospital Meyer, University of Florence, Florence, Italy.
Giancarlo la MarcaNewborn Screening, Clinical Chemistry and Pharmacology Laboratory, Meyer Children's University Hospital, Florence, Italy.
Mitsuhiro KatoDepartment of Pediatrics, Showa University School of Medicine and Epilepsy Medical Center, Showa University Hospital, Tokyo, Japan.
Kristin AndersonFounder and Research Liaison, 'ATP6V1A Families' Facebook group.
Carmen BarbaNeuroscience Department, Children's Hospital Meyer, University of Florence, Florence, Italy.ORCID 0000-0001-5445-5842
Luisa SturialeCNR, Institute for Polymers, Composites and Biomaterials, IPCB, 95126 Catania, Italy.
Domenico GarozzoCNR, Institute for Polymers, Composites and Biomaterials, IPCB, 95126 Catania, Italy.
Roberto BeiDepartment of Clinical Sciences and Translational Medicine, University of Rome 'Tor Vergata', Rome, Italy.
ATP6V1A collaborators
Laura MasuelliDepartment of Experimental Medicine, University of Rome 'Sapienza', Rome, Italy.
Valerio ContiNeuroscience Department, Children's Hospital Meyer, University of Florence, Florence, Italy.
Gaia NovarinoInstitute of Science and Technology Austria (ISTA), Klosterneuburg, Austria.
Anna FassioDepartment of Experimental Medicine, University of Genoa, Italy.
Meyer Children's Hospital · ITBoston Children's Hospital · USInstitute of Science and Technology Austria · ATBaylor College of Medicine · USChildren's Minnesota · USCincinnati Children's Hospital Medical Center · USFiladelfia · DKHaukeland University Hospital · NOItalian Institute of Technology · ITMarche Polytechnic University · ITMeta (Israel) · ILOspedale Policlinico San Martino · ITOulu University Hospital · FIThe University of Texas Health Science Center at Houston · USTranslational Genomics Research Institute · USUniversité Paris Cité · FRUniversity of Rome Tor Vergata · ITAmbry Genetics (United States) · USCentre National de la Recherche Scientifique · FRInstitute of Polymers, Composites and Biomaterials · IT

Funding

Pilot of New Technologies to Increase the Genomic Diagnosis of Undiagnosed Disease Network (UDN) PatientsU01HG007709 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI BACINO, CARLOS A., LEE, BRENDAN · 2014 to 2022
$14.3M
NHGRI NIH HHS U01 HG007709Wellcome Trust
6 · The paper itself

Abstract

Vacuolar-type H+-ATPase (V-ATPase) is a multimeric complex present in a variety of cellular membranes that acts as an ATP-dependent proton pump and plays a key role in pH homeostasis and intracellular signalling pathways. In humans, 22 autosomal genes encode for a redundant set of subunits allowing the composition of diverse V-ATPase complexes with specific properties and expression. Sixteen subunits have been linked to human disease. Here we describe 26 patients harbouring 20 distinct pathogenic de novo missense ATP6V1A variants, mainly clustering within the ATP synthase α/β family-nucleotide-binding domain. At a mean age of 7 years (extremes: 6 weeks, youngest deceased patient to 22 years, oldest patient) clinical pictures included early lethal encephalopathies with rapidly progressive massive brain atrophy, severe developmental epileptic encephalopathies and static intellectual disability with epilepsy. The first clinical manifestation was early hypotonia, in 70%; 81% developed epilepsy, manifested as developmental epileptic encephalopathies in 58% of the cohort and with infantile spasms in 62%; 63% of developmental epileptic encephalopathies failed to achieve any developmental, communicative or motor skills. Less severe outcomes were observed in 23% of patients who, at a mean age of 10 years and 6 months, exhibited moderate intellectual disability, with independent walking and variable epilepsy. None of the patients developed communicative language. Microcephaly (38%) and amelogenesis imperfecta/enamel dysplasia (42%) were additional clinical features. Brain MRI demonstrated hypomyelination and generalized atrophy in 68%. Atrophy was progressive in all eight individuals undergoing repeated MRIs. Fibroblasts of two patients with developmental epileptic encephalopathies showed decreased LAMP1 expression, Lysotracker staining and increased organelle pH, consistent with lysosomal impairment and loss of V-ATPase function. Fibroblasts of two patients with milder disease, exhibited a different phenotype with increased Lysotracker staining, decreased organelle pH and no significant modification in LAMP1 expression. Quantification of substrates for lysosomal enzymes in cellular extracts from four patients revealed discrete accumulation. Transmission electron microscopy of fibroblasts of four patients with variable severity and of induced pluripotent stem cell-derived neurons from two patients with developmental epileptic encephalopathies showed electron-dense inclusions, lipid droplets, osmiophilic material and lamellated membrane structures resembling phospholipids. Quantitative assessment in induced pluripotent stem cell-derived neurons identified significantly smaller lysosomes. ATP6V1A-related encephalopathy represents a new paradigm among lysosomal disorders. It results from a dysfunctional endo-lysosomal membrane protein causing altered pH homeostasis. Its pathophysiology implies intracellular accumulation of substrates whose composition remains unclear, and a combination of developmental brain abnormalities and neurodegenerative changes established during prenatal and early postanal development, whose severity is variably determined by specific pathogenic variants.

Indexed as

Brain DiseasesEpilepsyIntellectual DisabilitySpasms, InfantileVacuolar Proton-Translocating ATPasesAdenosine TriphosphateAtrophyChildHomeostasisHumansInfantLysosomesPhenotypeAdenosine TriphosphateATP6V1A protein, humanVacuolar Proton-Translocating ATPasesATP6V1Adevelopmental delayepileptic encephalopathylysosomal disorderprogressive brain atrophy

Identifiers

PMID35675510
PMCPMC10893886
OpenAlexW4226371602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.